|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02393 YESTAR HEALTH
Nominal 
0.071 +0.004 (+5.970%) | 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Turnover | 2,912,733 | -32.167% | 4,293,982 | 4,930,692 | 4,106,938 | 4,903,268 |
| Cost of Sales | (2,399,951) | -33.061% | (3,585,273) | (4,081,997) | (3,300,058) | (3,637,961) |
| Gross Profit | 512,782 | -27.646% | 708,709 | 848,695 | 806,880 | 1,265,307 |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | 38,837 | -- | (142,004) | (7,321) | (25,279) | (9,469) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 0 | -- | 19,731 | 7,994 | 5,247 | (9,166) | |
| Profit / (Loss) before Taxation | 41,040 | -- | (1,107,342) | 59,942 | (692,595) | 450,893 | |
| Taxation | (39,562) | -- | 86,748 | (47,263) | 47,297 | (149,639) | |
| Profit / (Loss) from Discontinued Operations | (2,749) | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (12,617) | -- | 28,362 | (9,352) | 54,813 | (98,581) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | (13,888) | -98.600% | (992,232) | 3,327 | (590,485) | 202,673 | |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 162,318 | -44.601% | 292,996 | 160,942 | 112,729 | 127,319 |
| Depreciation & Amortisation | 81,010 | -64.897% | 230,776 | 232,905 | 251,251 | 249,708 |
| Directors' Emoluments | 7,062 | -4.192% | 7,371 | 12,035 | 10,694 | 11,406 |
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| Auditor's Opinion Status | Unqualified (Modified Report) | -- | Disclaimer | Unqualified | Unqualified (Modified Report) | Unqualified |
Market Valuation Indicators
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| EPS (cts) | -0.600 | -98.592% | -42.600 | 0.100 | -25.000 | 8.500 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | 0.166 | -- | (0.039) | 0.305 | 0.284 | 0.181 |
| NBV per share ($) | (0.196) | -- | (0.175) | 0.324 | 0.321 | 0.494 |
| Remarks: | Real time quote last updated: 04/12/2024 14:04 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 1,089,239 |
| %Change | 30014.432% |
| EPS / (LPS) | RMB 0.470 |
| NBV Per Share (¥) | RMB 0.265 |